Table 2

Characteristics of patients identified by mHOMR

Site 1Site 2
Phase 1Phase 2P value*Effect size†Phase 1Phase 2P value*Effect size†
Age (months) (SD)83 (7.7)82 (7.7)0.29284 (8.2)84 (7.8)0.665
Sex (N)52 F/48 M40 F/60 M0.11941 F/59 M47 F/53 M0.476
Length of stay (median (IQR))5 (5)6 (6)0.2415 (8)5 (8)0.656
DNR order on admission (%)38%39%0.99937%33%0.656
Survival to discharge (%)97%84%0.0020.2286%90%0.514
Overall PC/GoC instances‡ (%)18%34%0.0160.1853%45%0.322
PC/GoC by Dx (%) (n/N)§
 Cancer53% (9/17)54% (15/28)0.99953% (8/15)100% (18/18)0.002¶0.57
 Chronic organ failure13% (2/15)31% (8/26)0.274¶40% (10/25)52% (13/25)0.570
 Frailty10% (7/68)25% (11/43)0.06260% (35/58)28% (14/50)0.0020.32
  • *Tests compared Phase 1 and Phase 2, within each site—Student’s t-test for age, Mann-Whitney-Wilcoxon test for length of stay and Pearson’s χ2 tests with Yates’ continuity correction for all other variables.

  • †Cohen’s d for t-tests, r for Mann-Whitney-Wilcoxon tests, Cramér’s V for χ2 tests.

  • ‡PC/GoC instances includes all consultations with PC and/or documented GoC discussions which occurred with the patient.

  • §Number of PC/GoC instances by diagnosis (n) over the total number of patients with that diagnosis (N).

  • ¶A χ2 test with Monte Carlo simulation was done due <5 samples per cell.

  • DNR, Do Not Resusitate; Dx, Diagnosis; GoC, goals of care; PC, palliative care; mHOMR, modified version of Hospitalised-patient One-year Mortality Risk.